Insight

Pashtoon Kasi: With BOT/BAL in our NEST trial, we are seeing ctDNA decline and CLEAR within days to 2-4 weeks

Photo from Pashtoon Kasi/LinkedIn

Mar 26, 2024, 15:02

Pashtoon Kasi: With BOT/BAL in our NEST trial, we are seeing ctDNA decline and CLEAR within days to 2-4 weeks

Pashtoon Kasi, Director for Colorectal Cancer Research at Weill Cornell Medicine shared on LinkedIn:

“We grossly underestimate how quickly immunotherapy can work. Especially with BOT/BAL (botensilimab) in our NEST trial, we are seeing ctDNA decline and CLEAR within days to 2-4 weeks. Unprecedented!

March is Colorectal Cancer Awareness Month.”

No alternative text description for this image

Proceed to the article.
Source: Pashtoon Kasi/LinkedIn

BOT/BAL botensilimab cancer colorectal cancer Colorectal Cancer Awareness Month immunotherapy for colorectal cancer NEST trial OncoDaily Oncology Pashtoon Kasi Weill Cornell Medicine

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage